| Advantages | They maintain tumor heterogeneity, support long-term expansion, and recapitulate the architecture and treatment response patterns of clinical breast cancers, providing a physiologically relevant platform for translational oncology research. |
| Species | Human |
| Product Type | PDX-derived Organoid |
| Growth Properties | Embedded 3D Culture |
| Growth Conditions | Cultured at 37°C under 95% air and 5% CO2. |
| Quality Control | Negative for mycoplasma, bacteria, yeast, and fungi. |
| Tissue | Breast |
| Disease | Invasive Ductal Carcinoma |
| Format | Frozen |
| Organoid Characterization | Generated from tumor-resident stem-like cells, these organoids preserve the pathological, genetic, and phenotypic features of the original tumor, including ER, PR, and HER2 receptor status. |
| Applications | Human breast cancer organoids are advanced preclinical tools suitable for drug screening, hormonal therapy evaluation, and molecular profiling. They are particularly well-suited for studies of breast cancer and receptor-defined subtypes, enabling precise assessment of drug efficacy and resistance mechanisms. These organoids support personalized therapy development by modeling patient-specific tumor behavior and can be used in co-culture systems for immunotherapy and tumor microenvironment research. Their PDX origin enhances clinical relevance for the development of next-generation targeted therapies. |
| Storage | Liquid Nitrogen |
| Shipping Information | Dry Ice |
For preclinical research and development use only; not intended for therapeutic or other applications.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.